The global TNF alpha inhibitors market is expected to touch $54.2 billion by 2025

Bangalore, India, August 13, 2019: With its recently published study “Global TNF Alpha Inhibitors Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025”, Infoholic Research forecasts that the global TNF alpha inhibitors market will continue to grow, owing to increased spending on R&D by pharmaceutical companies, higher prevalence of chronic autoimmune diseases globally, and constant research to develop target-based biologics. Continuous development of biosimilars and evolving market opportunities are poised to support the market growth during the forecast period 2019–2025.

Get a sample copy of the report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=14466

The global TNF alpha inhibitors market, by drug class, is segmented into adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. Among these, adalimumab occupied a dominant share in 2018, and golimumab is expected to grow at a high CAGR during the forecast period 2019–2025. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made adalimumab the largest revenue contributor in 2018. Currently, many companies are heavily investing to develop innovative products and enjoy the first-mover’s advantage in the market; this will be crucial at a point as soon as biologics lose their patents. Adalimumab has the highest number of ongoing clinical trials among various TNF alpha inhibitors, followed by certolizumab pegol.

Access Full Report Summary @ https://www.infoholicresearch.com/report/tnf-alpha-inhibitors-market

North America occupied a significant share in the TNF alpha inhibitors market in 2018, and Europe is also likely to grow at a high CAGR during the forecast period. Many companies, including Amgen, have filed the majority of their patents in the US, which provides them more extended exclusivity in North America. Growing R&D investments to develop new drugs and increasing efforts to accept biosimilars further make Europe the fastest-growing region.

“The global TNF alpha inhibitors market is growing at a low single-digit CAGR, and key companies are launching new drugs to increase their share in the market. For instance, in October 2018, Amgen announced the launch of its first inflammation biosimilar “AMGEVITA”, a biosimilar to adalimumab in markets across Europe. Besides, there are a considerable number of molecules in late-stage clinical trials (Phase III), which are expected to be launched soon and they seemingly pose a threat to the existing drugs in the market.” opined Arpitha Shetty, Research Analyst, Infoholic Research

Key Segments of the Report Include:

• TNF Alpha Inhibitors Market By Drug Class:
  • Adalimumab
  • Certolizumab Pegol
  • Etanercept
  • Golimumab
  • Infliximab
• TNF Alpha Inhibitors Market By Pipeline Analysis:
  • Phase I
  • Phase II
  • Phase III
• TNF Alpha Inhibitors Market By Regions:
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
• Industry Outlook: Market trends, drivers, restraints, and opportunities

Contact: Ms. Kathakali Basu

Infoholic Research LLP

IND: 080-461-51400

USA: 1-661-210-1186

kathakali@infoholicresearch.com